Right on cue with snappy repartee:)
Printable View
Singapore and Asia take their lead and look to US for guidance when it comes to healthcare and the latest developments - believe you me as one of my contacts is head of one of the private hospitals there.
Has PEB explained why NZ, Australia and Spain are such dismal failures for CXBladder?
$150,000 external sales in 20105 after 4 years! Whatever happened to home advantage?
First questions asked by excited health professionals in other exciting countries with excitable opportunities will be around success of sales in existing markets.
Beg to rephrase - "First excited questions asked by excited health professionals in other exciting countries with excitable opportunities will be around success of exciting sales in existing super excited markets'.
Now that's more to PEB's PR standard. :D
PS. In all seriousness, the use of the word 'excite' (one with also excited which implied 4 excite) in 2 sentences in their results announcement is worrying. The hype is now wearing off so use more 'excite'.
From my knowledge of the SE Asian market, institutions there don't sit around waiting for a lead from the US, especially when they've got wealthy international patients clamouring for the latest and best treatment and willing to pay big bucks for it, and have top-qualified specialists able to assess what is the best, as in Singapore.
As regards Spain, yes DD has explained the delay there. PEB's Spanish partner wasn't so interested in CxBladder Detect but is ready to roll when another part of the CXBladder suite becomes available inthe next few months.
Couta - I like to see differing viewpoints on a thread - you can always disagree with their thoughts but often there is a kernel of truth there as well. This company does seem to be a faith stock - you either believe or you don't! I don't hold but am following. It sort of reminds me WDT unfortunately...regards!